Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hip fracture

New Treatments Needed to Prevent Fractures in Osteoporosis

Ellen M. Field, MD, FACR, CCD  |  

Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

  |  

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

Why Would You Ever Write a Letter of Recommendation or Support?

Marian T. Hannan, DSc, MPH  |  

I vividly recollect asking my physics professor for a letter of recommendation. I sat in the front row of his lectures and visited his office hours most weeks in the semester. He turned me down because he was “too busy.” I was devastated—and panicked about asking my next choice for letter writer. On the plus…

Highlights from the ACR Review Course 2022

  |  

PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….

Challenging Cases in Osteoporosis: Tips from an Expert

  |  

Using three complicated patient cases, Kenneth G. Saag, MD, MSc, shared his expertise on osteoporosis and walked through his thought process and the literature, during a session of the 2022 ACR Education Exchange.

Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV

  |  

In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.